NEW HAVEN, Conn., July 05, 2022 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of Michael P. Miller to its Board of Directors, effective July 1, 2022. Mr. Miller brings nearly 40 years of strategic leadership and commercial growth experience in the pharmaceutical industry, where he most recently served as Executive Vice President, U.S. Commercial at Jazz Pharmaceuticals.
“We are pleased to welcome Mike to our Board and believe his deep commercial and market access expertise will be invaluable, especially now that the trade launch for IGALMI™ sublingual film is underway,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. “Mike’s significant industry experience with initial and expanded-indication product launches, along with his development and operational knowledge in both neuroscience and oncology, will be a critical resource to the Company at this key time of growth, as we optimize our commercial capabilities and continue to advance our pipeline.”
While at Jazz Pharmaceuticals, Mr. Miller led a 450+ person commercial team that generated $2.3 billion in revenues in 2020. Prior to Jazz, he served in senior executive management positions with commercial, marketing, market access, and sales responsibilities at VIVUS, Genentech (until acquisition by Roche), Connetics Corporation, and ALZA Corporation. He began his pharmaceutical career at Syntex Laboratories in various commercial roles until its acquisition by Roche. Mr. Miller currently sits on the Board of Puma Biotechnology and serves as an advisor to several private and public biotechnology companies. He previously sat on the Board of the Leukemia and Lymphoma Society, Silicon Valley and Monterey Chapter. Mr. Miller holds a B.S. in Finance from the University of San Francisco and an M.B.A. from San Francisco State University.
“I am excited to join the Board of BioXcel Therapeutics at this pivotal time, as this is an innovative company that I believe has strong commercial potential and is well-positioned for growth driven by its AI-based drug discovery and development platform,” said Mr. Miller. “I look forward to bringing my expertise to support the ongoing IGALMI launch efforts and collaborating with the rest of the Board and management team to continue bringing transformative medicines to patients in need.”
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The Company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine. BXCL501 is under investigation for the acute treatment of agitation associated with Alzheimer’s disease, and as an adjunctive treatment for major depressive disorder. The Company is also developing BXCL502 as a potential therapy for chronic agitation in dementia. Under its subsidiary OnkosXcel Therapeutics, the Company is developing BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. For more information, please visit www.bioxceltherapeutics.com.
